Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma*

Jennifer C. Ho; Bouthaina S. Dabaja; Sarah A. Milgrom; Grace L. Smith; Jay P. Reddy; Ali Mazloom; Ken H. Young; Lijuan Deng; L. Jeffrey Medeiros; Wenli Dong; Pamela K. Allen; Therese Y. Andraos; Nathan H. Fowler; Loretta J. Nastoupil; Yasuhiro Oki; Luis E. Fayad; Francesco Turturro; Sattva S. Neelapu; Jason Westin; Fredrick B. Hagemeister; Maria Alma Rodriguez; Chelsea C. Pinnix

doi:10.1080/10428194.2017.1312381

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma^*

Jennifer C. Ho, Bouthaina S. Dabaja, Sarah A. Milgrom, Grace L. Smith, Jay P. Reddy, Ali Mazloom, Ken H. Young, Lijuan Deng, L. Jeffrey Medeiros, Wenli Dong, Pamela K. Allen, Therese Y. Andraos, Nathan H. Fowler, Loretta J. Nastoupil, Yasuhiro Oki, Luis E. Fayad, Francesco Turturro, Sattva S. Neelapu, Jason Westin, Fredrick B. HagemeisterMaria Alma Rodriguez, Chelsea C. Pinnix

Research output: Contribution to journal › Article › peer-review

10 Scopus citations

Abstract

In 120 Stage I–IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall, progression free, testicular relapse free, and CNS relapse free survival (OS, PFS, TRFS, and CRFS, respectively). Seventy percent of patients received RT, 53% received anthracyclines and rituximab (modern therapy), and 61% received CNS prophylaxis. On univariate analysis RT was associated with improved TRFS, PFS, and trended toward improved OS. On multivariate analysis (MVA), RT was significantly associated with improved OS and PFS; the PFS benefit persisted among patients receiving modern therapy. CNS prophylaxis was associated with improved OS, PFS, and TRFS, but not CRFS on univariate analysis, and was not significant on MVA. RT is associated with improved survival, and should be considered for all testicular DLBCL patients, but additional strategies are needed to prevent CNS relapse.

Original language	English (US)
Pages (from-to)	2833-2844
Number of pages	12
Journal	Leukemia and Lymphoma
Volume	58
Issue number	12
DOIs	https://doi.org/10.1080/10428194.2017.1312381
State	Published - Dec 2 2017

Keywords

Testicular
intrathecal chemotherapy
lymphoma
radiation therapy
rituximab

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1080/10428194.2017.1312381

Cite this

Ho, J. C., Dabaja, B. S., Milgrom, S. A., Smith, G. L., Reddy, J. P., Mazloom, A., Young, K. H., Deng, L., Medeiros, L. J., Dong, W., Allen, P. K., Andraos, T. Y., Fowler, N. H., Nastoupil, L. J., Oki, Y., Fayad, L. E., Turturro, F., Neelapu, S. S., Westin, J., ... Pinnix, C. C. (2017). Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma^* Leukemia and Lymphoma, 58(12), 2833-2844. https://doi.org/10.1080/10428194.2017.1312381

Ho, JC, Dabaja, BS, Milgrom, SA, Smith, GL , Reddy, JP, Mazloom, A, Young, KH, Deng, L, Medeiros, LJ , Dong, W, Allen, PK, Andraos, TY, Fowler, NH, Nastoupil, LJ, Oki, Y, Fayad, LE, Turturro, F, Neelapu, SS , Westin, J, Hagemeister, FB, Rodriguez, MA & Pinnix, CC 2017, 'Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma^* ', Leukemia and Lymphoma, vol. 58, no. 12, pp. 2833-2844. https://doi.org/10.1080/10428194.2017.1312381

@article{a9ea51a296b8407fb0e1d543e78c376c,

title = "Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma* ",

abstract = "In 120 Stage I–IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall, progression free, testicular relapse free, and CNS relapse free survival (OS, PFS, TRFS, and CRFS, respectively). Seventy percent of patients received RT, 53% received anthracyclines and rituximab (modern therapy), and 61% received CNS prophylaxis. On univariate analysis RT was associated with improved TRFS, PFS, and trended toward improved OS. On multivariate analysis (MVA), RT was significantly associated with improved OS and PFS; the PFS benefit persisted among patients receiving modern therapy. CNS prophylaxis was associated with improved OS, PFS, and TRFS, but not CRFS on univariate analysis, and was not significant on MVA. RT is associated with improved survival, and should be considered for all testicular DLBCL patients, but additional strategies are needed to prevent CNS relapse.",

keywords = "Testicular, intrathecal chemotherapy, lymphoma, radiation therapy, rituximab",

author = "Ho, {Jennifer C.} and Dabaja, {Bouthaina S.} and Milgrom, {Sarah A.} and Smith, {Grace L.} and Reddy, {Jay P.} and Ali Mazloom and Young, {Ken H.} and Lijuan Deng and Medeiros, {L. Jeffrey} and Wenli Dong and Allen, {Pamela K.} and Andraos, {Therese Y.} and Fowler, {Nathan H.} and Nastoupil, {Loretta J.} and Yasuhiro Oki and Fayad, {Luis E.} and Francesco Turturro and Neelapu, {Sattva S.} and Jason Westin and Hagemeister, {Fredrick B.} and Rodriguez, {Maria Alma} and Pinnix, {Chelsea C.}",

note = "Publisher Copyright: {\textcopyright} 2017 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2017",

month = dec,

day = "2",

doi = "10.1080/10428194.2017.1312381",

language = "English (US)",

volume = "58",

pages = "2833--2844",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "12",

}

TY - JOUR

T1 - Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma*

AU - Ho, Jennifer C.

AU - Dabaja, Bouthaina S.

AU - Milgrom, Sarah A.

AU - Smith, Grace L.

AU - Reddy, Jay P.

AU - Mazloom, Ali

AU - Young, Ken H.

AU - Deng, Lijuan

AU - Medeiros, L. Jeffrey

AU - Dong, Wenli

AU - Allen, Pamela K.

AU - Andraos, Therese Y.

AU - Fowler, Nathan H.

AU - Nastoupil, Loretta J.

AU - Oki, Yasuhiro

AU - Fayad, Luis E.

AU - Turturro, Francesco

AU - Neelapu, Sattva S.

AU - Westin, Jason

AU - Hagemeister, Fredrick B.

AU - Rodriguez, Maria Alma

AU - Pinnix, Chelsea C.

PY - 2017/12/2

Y1 - 2017/12/2

N2 - In 120 Stage I–IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall, progression free, testicular relapse free, and CNS relapse free survival (OS, PFS, TRFS, and CRFS, respectively). Seventy percent of patients received RT, 53% received anthracyclines and rituximab (modern therapy), and 61% received CNS prophylaxis. On univariate analysis RT was associated with improved TRFS, PFS, and trended toward improved OS. On multivariate analysis (MVA), RT was significantly associated with improved OS and PFS; the PFS benefit persisted among patients receiving modern therapy. CNS prophylaxis was associated with improved OS, PFS, and TRFS, but not CRFS on univariate analysis, and was not significant on MVA. RT is associated with improved survival, and should be considered for all testicular DLBCL patients, but additional strategies are needed to prevent CNS relapse.

AB - In 120 Stage I–IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall, progression free, testicular relapse free, and CNS relapse free survival (OS, PFS, TRFS, and CRFS, respectively). Seventy percent of patients received RT, 53% received anthracyclines and rituximab (modern therapy), and 61% received CNS prophylaxis. On univariate analysis RT was associated with improved TRFS, PFS, and trended toward improved OS. On multivariate analysis (MVA), RT was significantly associated with improved OS and PFS; the PFS benefit persisted among patients receiving modern therapy. CNS prophylaxis was associated with improved OS, PFS, and TRFS, but not CRFS on univariate analysis, and was not significant on MVA. RT is associated with improved survival, and should be considered for all testicular DLBCL patients, but additional strategies are needed to prevent CNS relapse.

KW - Testicular

KW - intrathecal chemotherapy

KW - lymphoma

KW - radiation therapy

KW - rituximab

UR - http://www.scopus.com/inward/record.url?scp=85019053895&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019053895&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1312381

DO - 10.1080/10428194.2017.1312381

M3 - Article

C2 - 28482717

AN - SCOPUS:85019053895

SN - 1042-8194

VL - 58

SP - 2833

EP - 2844

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 12

ER -